{{Rsnum
|rsid=4833837
|Gene=IL21
|Chromosome=4
|position=122615808
|Orientation=plus
|GMAF=0.1997
|Gene_s=IL21
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 39.8 | 47.8 | 12.4
| HCB | 73.5 | 25.0 | 1.5
| JPT | 76.1 | 23.9 | 0.0
| YRI | 91.8 | 8.2 | 0.0
| ASW | 91.2 | 8.8 | 0.0
| CHB | 73.5 | 25.0 | 1.5
| CHD | 78.9 | 20.2 | 0.9
| GIH | 69.3 | 27.7 | 3.0
| LWK | 86.4 | 13.6 | 0.0
| MEX | 69.0 | 27.6 | 3.4
| MKK | 69.2 | 29.5 | 1.3
| TSI | 50.0 | 39.2 | 10.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=24389496
|Title=Interleukin (IL)-21 promoter polymorphism increases the risk of thyroid cancer in Chinese population
}}

{{PMID Auto
|PMID=18254984
|Title=Screening of functional and positional candidate genes in families with common variable immunodeficiency.
|OA=1
}}

{{PMID Auto
|PMID=19546505
|Title=IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
|OA=1
}}

{{PMID Auto
|PMID=20184734
|Title=The 4q27 locus and prostate cancer risk.
|OA=1
}}

{{PMID Auto
|PMID=24879484
|Title=Interleukin-21 Polymorphism Affects Gene Expression and is Associated with Risk of Ischemic Stroke
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}